HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

adamantanine

inhibitor of amino acid transport; RN given refers to parent cpd

Also Known As:

adamantanine hydrochloride; 2-aminoadamantane-2-carboxylic acid

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Bridged-Ring Compounds: 1
      - Adamantane: 182
        Amantadine: 2438
        adamantanine: 1

Experts

1.	Pieczykolan, Michał: 1 article (02/2016)
2.	Stecko, Sebastian: 1 article (02/2016)
3.	Szcześniak, Piotr: 1 article (02/2016)

Related Diseases

1.	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 02/05/2016 - "The developed method has been successfully applied in the synthesis of two bioactive peptides: 2-aminoadamantane-2-carboxylic acid derived P2X7-evoked glutamate release inhibitor and 4-amino-tetrahydropyranyl-4-carboxylic acid derived dipeptide GSK-2793660, which is currently in clinical trials as cathepsin C inhibitor for the treatment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis. "
2.	Fibrosis (Cirrhosis) 02/05/2016 - "The developed method has been successfully applied in the synthesis of two bioactive peptides: 2-aminoadamantane-2-carboxylic acid derived P2X7-evoked glutamate release inhibitor and 4-amino-tetrahydropyranyl-4-carboxylic acid derived dipeptide GSK-2793660, which is currently in clinical trials as cathepsin C inhibitor for the treatment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis. "
3.	Cystic Fibrosis (Mucoviscidosis) 02/05/2016 - "The developed method has been successfully applied in the synthesis of two bioactive peptides: 2-aminoadamantane-2-carboxylic acid derived P2X7-evoked glutamate release inhibitor and 4-amino-tetrahydropyranyl-4-carboxylic acid derived dipeptide GSK-2793660, which is currently in clinical trials as cathepsin C inhibitor for the treatment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis. "
4.	Bronchiectasis 02/05/2016 - "The developed method has been successfully applied in the synthesis of two bioactive peptides: 2-aminoadamantane-2-carboxylic acid derived P2X7-evoked glutamate release inhibitor and 4-amino-tetrahydropyranyl-4-carboxylic acid derived dipeptide GSK-2793660, which is currently in clinical trials as cathepsin C inhibitor for the treatment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis. "

Related Drugs and Biologics

1.	Cathepsin C
2.	Glutamic Acid (Glutamate)
3.	Peptides (Polypeptides)
4.	Dipeptides
5.	4-amino-tetrahydropyranyl-4-carboxylic acid
6.	GSK-2793660